Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-escalation study of subcutaneous Hematide in chemotherapy-induced anemia
2005-003354-10Phase 2Completed
- Sponsor
- Affymax, Inc.
- Start
- Aug 2005
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of peginesatide in anaemia (4 cohorts), sponsored by Affymax, Inc. Primary endpoints: Hemoglobin increase at week 9, Hemoglobin increase at weeks 3, 6, and 12 and 9 more. Started Aug 2005; status: completed.
02
Drugs
peginesatide
03
Conditions
anaemia
Beyond the preview
Go deeper on 2005-003354-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003354-10.